How Can AI Support Clinical Study Design? Opportunities, Limitations, and Human Judgment

Clinical study design has never been simply about writing a Protocol.

Before formal drafting begins, the development team must already address a series of interconnected questions: What is the objective of the study? Who is the target population? How should dose and administration be structured? Which safety signals need to be monitored? How should endpoints be defined? Under what circumstances should the study be stopped or modified?

As generative AI enters clinical development workflows, new possibilities are emerging.

AI can rapidly organize large volumes of background information, compare different design options, generate structured question lists, and help translate confirmed design decisions into a Protocol Synopsis or an initial Protocol draft. Tasks that once required substantial manual searching, organization, and repeated rewriting can now be accelerated.

But this raises a more important question:

AI can help design a clinical study—but should it make clinical study design decisions on behalf of humans?

AI Is Best Used First for Information-Intensive Work

During the early stages of study design, the first challenge is often not a lack of information, but that the information is fragmented.

Scientific background, nonclinical findings, existing human data, experience with comparable products, development strategy, and input from different functional teams may be distributed across multiple documents and versions.

At this stage, one of AI’s most immediate benefits is its ability to support information-intensive work.

For example, AI can help organize existing evidence, compare information across sources, identify information gaps, generate a structured list of design questions, and organize confirmed inputs into a clearer study design framework.

This can help a development team move more quickly from:

“We have a large amount of information”

to:

“What do we actually need to decide?”

Organizing Options Is Not the Same as Making Decisions

Clinical study design quickly moves beyond information organization.

Questions such as dose selection, definition of the study population, selection of the primary endpoint, dose-escalation strategy, and stopping criteria are not simply writing problems.

They may simultaneously involve nonclinical evidence, clinical pharmacology, medical judgment, statistics, regulatory strategy, and the Sponsor’s assessment of the broader development program.

AI can help structure these questions and generate possible options. But an answer that appears reasonable is not the same as a development decision that is ready to be adopted.

A more mature workflow is therefore not:

AI generates the Study Design → Human approves it

Instead, it is:

AI organizes evidence and options → The team identifies unresolved questions → Relevant SMEs apply professional judgment → The Sponsor confirms key development decisions → Confirmed decisions are translated into formal documents

The sequence matters.

Faster Document Production Makes Human Roles More Explicit

As AI makes it possible to generate a Synopsis or initial Protocol draft more quickly, the scarce work begins to shift away from simply producing text.

The more important questions become:

Are the sources reliable?

Are inputs from different functions consistent?

Which elements have been confirmed?

Which remain working assumptions?

Who owns each decision?

When does an issue need to be escalated to the appropriate SME?

This is one of the implications of AI adoption in clinical development that can easily be overlooked.

Production speed can increase, but decision ownership does not disappear.

In fact, as documents can be generated more quickly, teams need to distinguish even more clearly between:

Who produces the work, who makes the judgment, and who retains final accountability.

The Value of AI Is Not to Replace Study Design, but to Make the Process More Efficient

AI’s appropriate role in clinical study design should therefore not be understood as “automatically designing a clinical study.”

Its more practical value is to help teams organize evidence faster, identify gaps earlier, compare options more efficiently, and translate professional decisions into documents that can be discussed, reviewed, and ultimately executed.

AI can shorten the distance between information and an initial draft.

But between an initial draft and an actual development decision, professional judgment from the clinical development team, the Sponsor, and the relevant SMEs remains essential.

AI can accelerate the production layer of Study Design. But where the study should go remains a human decision.